Dr (Colon Cancer)

Colon adenocarcinoma (COAD) is the commonest colon cancer exhibiting high
mortality. Due to the association with cancers progression, long noncoding
RNAs (lncRNAs) become prognostic biomarkers. This study, using relevant
clinic information and expression profiles of lncRNA originating in The
Cancer Genome Atlas database, aims to construct a prognostic lncRNA
signature to estimate the prognosis for patients. In the training cohort,
prognosis related lncRNAs were selected from differently expressed lncRNAs
by univariate Cox analysis. Furthermore, the least absolute shrinkage and
selection operator (LASSO) regress and multivariate Cox analysis were
employed for identifying prognostic lncRNAs. The prognostic signature was
constructed by those lncRNAs. Prognostic model was able to calculate each
COAD patient’s risk score and split the patients to groups of low and high
risk. Compared to the low-risk group, the high-risk group had significant
poor prognosis. Then, the prognostic signature was validated in validation
and all cohorts. The receiver operating characteristic (ROC) curve and
c-index were performed in all cohort. Moreover, those prognostic lncRNAs
signature were combined with clinicopathological risk factors to construct
a nomogram for predicting the prognosis of COAD in clinic. Finally, 7
lncRNAs (CTC-273B12.10, AC009404.2, AC073283.7, RP11-167H9.4, AC007879.7,
RP4-816N1.7, RP11-400N13.2) were identified and validated by different
cohorts. The Kyoto Encyclopedia of Genes and Genomes analysis of the mRNAs
co-expressed with 7 prognostic lncRNAs suggested 4 significantly
up-regulated pathways, which are AGE-RAGE signaling pathway, focal
adhesion, ECM-receptor interaction and PI3K/Akt signaling pathway. To sum
up, our study verified that the mentioned 7 lncRNAs can be biomarkers to
predict the prognosis of COAD patients and design personalized treatment.